

RSV VACCINES FOR THE WORLD

18-20 November 2015, The Salk Institute, La Jolla, California, USA

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR RSVVW 2015

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to a past vaccine candidate led to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. Currently a wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, concerted efforts will lead researchers to reach the goal of attaining safe and effective RSV vaccines in the near future.

This second conference, following the RSVVW 2013 meeting held in Porto in 2013, will again aim to bring together RSV researchers and other interested parties and researchers to hear updates on progress towards the successful implementation of vaccines/vaccine strategies against the RSV pathogen. RSVVW 2015 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.

The RSVVW 2015 meeting will comprise keynote presentations and special sessions and in addition the RSVVW 2015 organisers invite oral and poster abstract submissions to be considered for inclusion in the meeting schedule.

SCIENTIFIC ADVISORY PANEL

Greg Glenn (*Novavax Inc., Rockville, Maryland, USA*)

Deborah Higgins (*PATH, Seattle, Washington, USA*)

James Crowe (*Vanderbilt University, Nashville, Tennessee, USA*)

Philip Dormitzer (*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

Trudy Morrison (*University of Massachusetts, Worcester, Massachusetts, USA*)

Alexis Kalergis (*Pontificia Universidad Catolica de Chile/University of Nantes, France*)

Sylvain Fleury (*Mymetics Corporation, Epalinges, Switzerland*)

Ali Fattom (*NanoBio Corporation, Ann Arbor, Michigan, USA*)

Sylvia van den Hurk (*VIDO, University of Saskatchewan, Canada*)

Kees Leenhouts (*Mucosis, Groningen, The Netherlands*)

Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)

Judy Beeler (*CBER/FDA, Bethesda, Maryland, USA*)

Jean-Francois Toussaint (*GSK Vaccines, Rixensart, Belgium*)

James Nokes (*KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK*)

CONFERENCE SCOPE

The RSVVW 2015 meeting is aimed at attracting a broader audience of RSV researchers and also vaccinologists/groups not necessarily directly involved with RSV research. The main topics/sessions will include:

Lessons learned from previous vaccine developments

Requirements induction of protective, safe and durable immune responses

Populations needing a vaccine and strategies for delivery

Infant Immunization – Maternal Immunization – Elderly Immunization

Current vaccines development

Clinical development of RSV vaccines: hurdles, opportunities and dead ends

Animal and challenge models

Antigens, adjuvants and vaccine approaches

RSV vaccines in the developing world



Abstract Submissions

The RSVW 2015 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during RSVW 2015. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (RSVW 2015 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for late breaker oral abstracts and poster abstracts is **Friday 23rd October 2015**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB Memory Stick which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to RSVW 2015. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at RSVW 2015. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- ☐ I wish to be placed on the mailing list to receive further information on RSVW 2015
- ☐ I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of Abstract:

Intended Session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please type/print):

- ☐ My organisation is interested in sponsoring RSVW 2015 ☐ Please send me details of exhibition/delegate pack insert service

REQUEST DETAILS OF FUTURE EVENTS

- ☐ **PLANT-BASED VACCINES ANTIBODIES & BIOLOGICS** – 8-10 June 2015, Lausanne, Switzerland
- ☐ **VACCINES FOR ENTERIC DISEASES** – 8-10 July 2015, Edinburgh, Scotland
- ☐ **INFLUENZA VACCINES FOR THE WORLD** – 6-9 October 2015, Albufeira, Portugal
- ☐ **HUMAN ANTIBODIES & HYBRIDOMAS** – 28-30 October 2015, Lausanne, Switzerland

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, RSVW 2015, MEETINGS MANAGEMENT

The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com

Website: www.meetingsmanagement.com/rsvw_2015